In addition to sclerotherapy and surgical excision, protein inhibitors involved in the signaling pathways PI3K/AKT/mTOR or RAS/BRAF/MAPK/ERK appear as targeted therapeutic options for different types of vascular malformations, so far, the clinical results being promising. Here, AKT1 is linked to vascular malformation.